摘要
目的分析血脂康联合熊去氧胆酸治疗非酒精性脂肪肝合并高脂血症的有效性及安全性。方法选取2021年6月至2022年6月上饶市立医院收治的48例非酒精性脂肪肝合并高脂血症患者作为研究对象,按照抽签法分为观察组(24例)与对照组(24例)。观察组采用血脂康联合熊去氧胆酸治疗,对照组采用熊去氧胆酸治疗。比较两组治疗前后的肝功能相关指标、血脂相关指标、临床有效性和不良反应发生情况。结果治疗后观察组患者的谷氨酰转肽酶(GGT)、丙氨酸转氨酶(ALT)、天门冬氨酸转氨酶(AST)水平均低于对照组,差异有统计学意义(P<0.05)。治疗后观察组患者的总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)低于对照组,高密度脂蛋白胆固醇(HDL-C)高于对照组,差异有统计学意义(P<0.05)。观察组患者的治疗总有效率为95.83%,高于对照组的70.83%,差异有统计学意义(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论非酒精性脂肪肝合并高脂血症采用熊去氧胆酸和血脂康联合治疗能够提高临床总有效率,帮助患者显著改善肝功能和血脂水平,同时用药方案有良好的安全性。
Objective To analyze the efficacy and safety of Xuezhikang combined with Ursodeoxycholic Acid in the treatment of nonalcoholic fatty liver disease with hyperlipidemia.Methods Forty-eight patients with nonalcoholic fatty liver disease combined with hyperlipidemia admitted to Shangrao Municipal Hospital from June 2021 to June 2022 were selected as the study objects,and they were divided into observation group(24 cases)and control group(24 cases)according to lottery method.The observation group was treated with Xuezhikang combined with Ursodeoxycholic Acid,while the control group was treated with Ursodeoxycholic Acid.Liver function related indexes,lipid related indexes,clinical effectiveness and occurrence of adverse reactions were compared between the two groups before and after treatment.Results After treatment,the levels of glutamyl transpeptidase(GGT),alanine transaminase(ALT),aspartate transaminase(AST)in the observation group were lower than those in the control group,with statistically significant differences(P<0.05).After treatment,the total cholesterol(TC),triacylglycerol(TG)and low-density lipoprotein cholesterol(LDL-C)in the observation group were lower than those in the control group,and high-density lipoprotein cholesterol(HDL-C)was higher than that in the control group,with statistically significant differences(P<0.05).The total effective rate of 95.83%in the observation group after treatment was higher than that of 70.83%in the control group,with statistically significant difference(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of ursodeoxycholic acid and Xuezhikang in the treatment of nonalcoholic fatty liver disease with hyperlipidemia can improve the overall clinical effective rate,help patients significantly improve liver function and blood lipid levels,and the medication regimen has good safety.
作者
曹亚利
易珍
杨宇
CAO Yali;YI Zhen;YANG Yu(Department of Gastroenterology,Shangrao Municipal Hospital,Jiangxi Province,Shangrao334000,China)
出处
《中国当代医药》
CAS
2023年第28期53-56,共4页
China Modern Medicine
基金
江西省上饶市科技计划一般项目(2021CZDX61)。
关键词
非酒精性脂肪肝
高脂血症
血脂康
熊去氧胆酸
不良反应
Non alcoholic fatty liver disease
Hyperlipidemia
Xuezhikang
Urodeoxycholic Acid
Adverse reactions
